IsoRay, Inc. (NYSEMKT:ISR) Reports 11% Revenue Growth During 2013 Quarter

961

Dallas, Texas 03/17/2014 (FINANCIALSTRENDS) –  IsoRay, Inc. (NYSEMKT: ISR) reported 11% revenue increase during 2013 Quarter. According to the reports the company witnessed revenue earnings growth from the addition of new facilities utilizing Cesium-131, earnings from continued accrual of patients under several active studies. The company also announced FDA has cleared Liquid Cesium-131. Liquid Cesium-131 will help company’s revenue increase by promoting IsoRay’s treatment along with GliaSite® balloon catheter as an alternative for treating recurring and complicated cancers located throughout the body. The company’s financial results continue to be impacted by Affordable Care Act and to ensure the company makes gain in the future sales IsoRay, Inc continues will invest in R&D data protocols.

IsoRay, Inc. (NYSEMKT:ISR) Obtains CE Mark Extension for Cesium-131

According to the reports, the company has received five year extension to its CE mark covering IsoRay’s entire product offering of Cesium-131 seeds, which further permits sales of company products in the European market until 2018. CE mark confirms the product adheres to required European commission directives. With the extension of CE mark, the company can continue marketing its products in European Free Trade Association (EFTA) member states as well as the European Union. According to company’s CEO the extension of CE mark, indicates the quality and care IsoRay places on producing a truly superior product and company can look forward towards positive gains.

IsoRay Product Lines Sales Cleared by Greek Governmental

The company announced it has received approvals from Greek Government for the sale of IsoRay’s complete product line in Greece. According to the company’s CEO, they are optimistic and looking forward to establish their footprint in Greek Market and thus expand their International network. The company with FDA Approval and CE mark has license to sell its products in US and 31 European nations.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.